Russia’s Petrovax Pharm to localize production in Iran

MOSCOW, Feb 19 (PRIME) -- Pharmaceutical company NPO Petrovax Pharm plans to transfer technologies for full-cycle anti-influenza vaccine production to Iranian company Sobhan Recombinant Protein in about two and a half years, becoming the first Russian drugs company to localize production in Iran, Petrovax Pharm said in a statement Friday.

The project will be supported by the Iranian government, the company said.

“The transfer of technologies for production of quadrivalent polymer-subunit anti-influenza vaccine developed by Petrovax Pharm is also planned in the framework of the agreement, as well as implementation of two large-scale projects,” the company said.

The first project encompasses Sobhan Recombinant Protein transferring technologies for full-cycle anti–serum hepatitis vaccine to Petrovax, while the second project implies another Iranian company CinnaGen transferring technologies for production of several biosimilars.

End